Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)

Lundbeck

Status and phase: Completed; Phase 3

Conditions: Insomnia

Treatments: Drug: Comparator: placebo; Drug: MK0928, gaboxadol

Study type: Interventional

Funder types: Industry

Identifiers

NCT00095043

0928-005

2004_088

MK0928-005

Details and patient eligibility

About

The purpose of this trial is to study the safety of MK0928 on insomnia in the elderly.

Full description

The duration of treatment is 1 year.

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of Insomnia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind